FDA Approves Novartis’s Kisqali For High-Risk Early Breast Cancer
FDA approves Novartis’s Kisqali (ribociclib) with an aromatase inhibitor for HR+/HER2- stage II and III early breast cancer at high recurrence risk.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
